Like Genaissance Pharmaceuticals, Inc.

announced 6/22/2005 via BNC Analysis

Clinical Data, Inc., will acquire Genaissance Pharmaceuticals, Inc.

synopsis: Clinical Data Inc. announced Tuesday that it will acquire Genaissance Pharmaceuticals in an all-stock transaction valued at $56 million. Genaissance shareholders will own 40 percent of the combined company when the deal closes sometime in the fourth quarter.
buyer: Clinical Data, Inc. (CLDA:$0.00)
Clinical Data, Inc. provides a full range of products and services to the growing domestic Physician Office Laboratory market and to smaller laboratories internationally & also provides a complete range of products and services for the Physician Office Laboratory and hospital laboratory market. "
target: Genaissance Pharmaceuticals, Inc.
Genaissance is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and Pharmacogenomic support services to the pharmaceutical industr
price ($mm)
$56
rev ($mm)
$21
EBITDA ($mm)
EV / rev
2.7x
EV / EBITDA
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/26/2010 via Market Wire

Unity Management Group, Inc, acquired Metropolitan Computer Corporation

synopsis: Unity Management Group, Inc announced that it has successfully completed the acquisition of Metropolitan Computer Corporation (MCC/ Legacy).
buyer: Unity Management Group, Inc (US:UYMG:$0.00)
Unity Management Group is a health resource company, which provides quality physician practice management services, that offer high value, and significant return, through its three subsidiary companies. United Healthcare Solutions, Unity Technologies Inc., and United Business Services. "
target: Metropolitan Computer Corporation
Metropolitan Computer Corporation (MCC/ Legacy) designs, engineers, markets, and services instrumentation equipment and software systems for increased efficiency within the pharmaceutical industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/2/2004 via BusinessWire

Apogent Technologies, Inc. merged with Fisher Scientific International Inc.,

synopsis: Fisher Scientific International Inc. (NYSE: FSH) today completed its approximately $4.0 billion merger with Apogent Technologies Inc. (formerly trading as NYSE: AOT), providing Fisher Scientific with a $1.1 billion footprint in the high-growth life-science market.
buyer parent: Thomas H. Lee Partners, L.P.
buyer: Fisher Scientific International Inc.
Fisher Scientific International, Inc. provides products and services to the scientific research and clinical laboratory markets. It operates in three segments: Scientific Products and Services, Healthcare Products and Services, and Laboratory Workstations. The Scientific Products and Services segmen"
target: Apogent Technologies, Inc.
Apogent Technologies Inc. is a developer and manufacturer of value-added products for the clinical and research markets. Over 80% of the Company's products are consumables. Apogent's operating subsidiaries manufacture most of their products in approximately 80 facilities worldwide. The Company's cu
price ($mm)
$3,991
rev ($mm)
$1,118
EBITDA ($mm)
$313
EV / rev
3.6x
EV / EBITDA
12.7x
announced 3/8/2016 via PR Newswire

Nordic Capital, will acquire ERT

synopsis: Genstar Capital, a leading private equity firm focused on the healthcare, software, financial services, and industrial technology industries, announced the sale of ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, to Nordic Capital Fund VIII.
buyer: Nordic Capital
Nordic Capital is a leader in Nordic private equity investments, and now has an enviable reputation in investment and portfolio management. Since launching in 1989, Nordic Capital funds have delivered outstanding returns for our investors. "
target parent: Genstar Capital LLC
target: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions.
price ($mm)
rev ($mm)
$300
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 7/3/2012 via PR Newswire

Genstar Capital LLC, acquired ERT

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations, announced that Genstar Capital, LLC, has completed its acquisition of the company in a take-private transaction.
buyer: Genstar Capital LLC
Genstar Capital LLC has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries. "
target: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives.
price ($mm)[EV]
$395 [$370]
rev ($mm)
$194
EBITDA ($mm)
$42
EV / rev
1.9x
EV / EBITDA
9.0x
announced 3/6/2012 via PR Newswire

CareFusion Corporation, will acquire PhACTs, LLC.

synopsis: CareFusion Corporation announced an agreement to acquire PHACTS, LLC, a Seattle-based technology and consulting company that helps hospital pharmacies better manage inventory, reduce pharmaceutical costs and streamline operations. Terms of the deal were not disclosed.
buyer: CareFusion Corporation (CFN:$3,598.00)
CareFusion Corporation is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. "
target: PhACTs, LLC.
PHACTS was formed to serve Health Systems with multiple hospitals and/or clinics, doctors' offices, surgery centers and other locations, which need to account for and provide medications and pharmacy supplies across their network.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/22/2005 via BNC Analysis

Clinical Data, Inc., will acquire Genaissance Pharmaceuticals, Inc.

synopsis: Clinical Data Inc. announced Tuesday that it will acquire Genaissance Pharmaceuticals in an all-stock transaction valued at $56 million. Genaissance shareholders will own 40 percent of the combined company when the deal closes sometime in the fourth quarter.
buyer: Clinical Data, Inc. (CLDA:$0.00)
Clinical Data, Inc. provides a full range of products and services to the growing domestic Physician Office Laboratory market and to smaller laboratories internationally & also provides a complete range of products and services for the Physician Office Laboratory and hospital laboratory market. "
target: Genaissance Pharmaceuticals, Inc.
Genaissance is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and Pharmacogenomic support services to the pharmaceutical industr
price ($mm)
$56
rev ($mm)
$21
EBITDA ($mm)
EV / rev
2.7x
EV / EBITDA
closed 4/15/2009 via BusinessWire

Beckman Coulter, Inc., acquired Cogenics

synopsis: Clinical Data, Inc. announced that it has completed the sale of Cogenics, the Company’s genomics services division, to Beckman Coulter, Inc. As previously announced, the sale achieves Clinical Data’s goal to monetize non-core assets and focus resources on advancing its two late-stage targeted therapeutic programs.
buyer: Beckman Coulter, Inc. (BEC:$0.00)
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. "
target parent: Clinical Data, Inc.
target: Cogenics
Cogenics’ genomics solutions span current and next generation sequencing, gene expression, clinical and non-clinical genotyping, biomanufacturing support, nucleic acid extraction and biobanking for both research and regulated environments.
price ($mm)
$14
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/15/2006 via BusinessWire

BioImagene, acquired Tissue Informatics Inc.

synopsis: BioImagene announced today the closing of its acquisition of TissueInformatics, from Icoria -- a business unit of Clinical Data Inc. This acquisition makes BioImagene the technological leader in tissue analysis and enriches their product portfolio from research to Tox-path. TissueInformatics is a pioneering company in tissue image analysis.
buyer: BioImagene
BioImagene provides sophisticated bio-image analysis products built on iHarness, its patent-pending technology platform. BioImagene's products allow physicians and researchers to analyze and interpret images with far greater speed and consistency. "
target parent: Clinical Data, Inc.
target: Tissue Informatics Inc.
A pioneering company in tissue image analysis, based in Pittsburgh, Pennsylvania. It specializes in the development and application of automated pathology software for the quantitative analysis of tissue changes in drug discovery, disease assessment, toxicology, and tissue engineering research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/20/2005 via BusinessWire

Icoria, Inc. merged with Clinical Data, Inc.,

synopsis: Clinical Data, Inc. announced that it has closed its previously announced acquisition of Icoria, Inc. following the approval of the merger by the stockholders of Icoria.
buyer: Clinical Data, Inc. (CLDA:$0.00)
Clinical Data, Inc. provides a full range of products and services to the growing domestic Physician Office Laboratory market and to smaller laboratories internationally & also provides a complete range of products and services for the Physician Office Laboratory and hospital laboratory market. "
target: Icoria, Inc.
Icoria is a biotechnology company focused on the discovery, development and commercialization of diagnostics and targeted therapeutics in diabetes, obesity, oncology and other areas of unmet medical need.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/22/2005 via BNC Analysis

Clinical Data, Inc., will acquire Genaissance Pharmaceuticals, Inc.

synopsis: Clinical Data Inc. announced Tuesday that it will acquire Genaissance Pharmaceuticals in an all-stock transaction valued at $56 million. Genaissance shareholders will own 40 percent of the combined company when the deal closes sometime in the fourth quarter.
buyer: Clinical Data, Inc. (CLDA:$0.00)
Clinical Data, Inc. provides a full range of products and services to the growing domestic Physician Office Laboratory market and to smaller laboratories internationally & also provides a complete range of products and services for the Physician Office Laboratory and hospital laboratory market. "
target: Genaissance Pharmaceuticals, Inc.
Genaissance is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and Pharmacogenomic support services to the pharmaceutical industr
price ($mm)
$56
rev ($mm)
$21
EBITDA ($mm)
EV / rev
2.7x
EV / EBITDA

Like Genaissance Pharmaceuticals, Inc.


read more

Genaissance Pharmaceuticals, Inc.

AAIPharma Services

Metropolitan Computer Corporation

Apogent Technologies, Inc.

ERT

ERT

PhACTs, LLC.

read more

Genaissance Pharmaceuticals, Inc.

read more

Cogenics

Tissue Informatics Inc.

Icoria, Inc.

Genaissance Pharmaceuticals, Inc.

read more
Geography
Matching Companies
Ticker: JNJ
 
 
 
 
 
 
 
 
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson engages in the research and development, manufacture, and sale of a range of products in the healthcare field. The company operates through three business segments, including Consumer; Pharmaceutical and Medical Devices; and Diagnostics.
year
2019
rev ($mm)
$81,325.00
EBITDA ($mm)
$27,998.00
EBIT ($mm)
$21,066.00
Net Income ($mm)
$16,332.00
Employees
135100
  • drill down
  • watch
Ticker: COV
 
 
 
 
 
 
 
 
Covidien
Covidien
Tyco Healthcare became Covidien and began independently trading on the New York and Bermuda Stock Exchanges on July 2, 2007, marking its debut as an independent diversified global healthcare products company.
year
2010
rev ($mm)
$10,429.00
EBITDA ($mm)
$2,628.00
EBIT ($mm)
$2,139.00
Net Income ($mm)
$1,632.00
Employees
41500
  • drill down
  • watch
Ticker: ASX:AVX
 
 
 
 
 
 
 
 
Avexa Limited
Avexa is a biotechnology company dedicated to the discovery and development of new drugs to treat serious infectious diseases, particularly Human Immunodeficiency Virus (HIV). They are based in Australia.
year
2015
rev ($mm)
$0.24
EBITDA ($mm)
($1.45)
EBIT ($mm)
($1.46)
Net Income ($mm)
Employees
5
  • drill down
  • watch
Ticker: MRK
 
 
 
 
 
 
 
 
Merck & Co., Inc.
Merck & Co., Inc.
Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they deliver health solutions.
year
2020
rev ($mm)
$48,081.00
EBITDA ($mm)
$19,058.00
EBIT ($mm)
$15,735.00
Net Income ($mm)
$10,147.00
Employees
71000
  • drill down
  • watch
Ticker: ENXTPA:BIM
 
 
 
 
 
 
 
 
bioMérieux S.A.
bioMérieux S.A.
A world leader in the field of in vitro diagnostics for 50 years, bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety.
year
2015
rev ($mm)
$1,996.55
EBITDA ($mm)
$404.73
EBIT ($mm)
$278.41
Net Income ($mm)
$155.44
Employees
9258
  • drill down
  • watch
Ticker: ENXTPA:DIM
 
 
 
 
 
 
 
 
Sartorius AG
Sartorius AG
Sartorius is a international pharmaceutical and laboratory equipment supplier. With their innovative products and services, they are helping their customers across the entire globe to implement their complex and quality-critical biomanufacturing and laboratory processes reliably and economically.
year
2016
rev ($mm)
$1,121.72
EBITDA ($mm)
$299.20
EBIT ($mm)
$257.20
Net Income ($mm)
$163.92
Employees
4590
  • drill down
  • watch
Ticker: XTRA:SBS
 
 
 
 
 
 
 
 
Stratec SE
Stratec SE
STRATEC SE designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers complex consumables for diagnostic and medical applications.
year
2019
rev ($mm)
$240.89
EBITDA ($mm)
$38.57
EBIT ($mm)
$21.94
Net Income ($mm)
$15.69
Employees
1223
  • drill down
  • watch
Ticker: CAH
 
 
 
 
 
 
 
 
Cardinal Health, Inc.
Cardinal Health, Inc.
Cardinal Health, Inc. improves the cost-effectiveness of the health care industry. Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability.
year
2018
rev ($mm)
$141,935.00
EBITDA ($mm)
$2,870.00
EBIT ($mm)
$1,860.00
Net Income ($mm)
Employees
50200
  • drill down
  • watch
Ticker: BDX
 
 
 
 
 
 
 
 
Becton, Dickinson and Company
Becton, Dickinson and Company
Becton, Dickinson and Company (BD) is a leading medical technology company. BD’s innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research.
year
2020
rev ($mm)
$17,117.00
EBITDA ($mm)
$4,569.00
EBIT ($mm)
$2,415.00
Net Income ($mm)
$874.00
Employees
65000
  • drill down
  • watch
Ticker: FMS
 
 
 
 
 
 
 
 
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA
As a vertically integrated company, we offer products and services for the entire dialysis value chain. The highest medical standards are our benchmark.
year
2009
rev ($mm)
$11,247.48
EBITDA ($mm)
$2,212.68
EBIT ($mm)
$1,755.60
Net Income ($mm)
$891.14
Employees
72812
  • drill down
  • watch
Ticker: FAGR
 
 
 
 
 
 
 
 
Fagron
Fagron
Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Fagron offers Fagron Compounding Essentials, Fagron Trademarks and Fagron Compounding Services to pharmacies and hospital pharmacies in 30 countries.
year
2014
rev ($mm)
$473.30
EBITDA ($mm)
$113.50
EBIT ($mm)
$96.32
Net Income ($mm)
$17.17
Employees
1902
  • drill down
  • watch
Ticker: ABT
 
 
 
 
 
 
 
 
Abbott Laboratories
Abbott Laboratories
Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.
year
2009
rev ($mm)
$30,764.71
EBITDA ($mm)
$8,220.25
EBIT ($mm)
$6,130.74
Net Income ($mm)
$5,745.84
Employees
73000
  • drill down
  • watch
Ticker: SYK
 
 
 
 
 
 
 
 
Stryker Corporation
Stryker Corporation
Stryker Corporation is one of the world's leading medical technology companies with the most broadly based range of products in orthopaedics and a significant presence in other medical specialties.
year
2016
rev ($mm)
$10,062.00
EBITDA ($mm)
$2,717.00
EBIT ($mm)
$2,312.00
Net Income ($mm)
$1,617.00
Employees
27000
  • drill down
  • watch
Ticker: HOLX
 
 
 
 
 
 
 
 
Hologic, Inc.
Hologic, Inc.
Hologic is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications.
year
2011
rev ($mm)
$1,789.35
EBITDA ($mm)
$595.38
EBIT ($mm)
$290.64
Net Income ($mm)
$157.15
Employees
5019
  • drill down
  • watch
Ticker: ASX:SFP
 
 
 
 
 
 
 
 
Safety Medical Products Ltd
Safety Medical Products Limited has various patents and registered trademarks associated with the SecureTouch syringe in regions and countries including Europe, the United States of America, Africa, Australia and New Zealand.
year
2013
rev ($mm)
EBITDA ($mm)
EBIT ($mm)
($0.77)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: CLDA
 
 
 
 
 
 
 
 
Clinical Data, Inc.
Clinical Data, Inc.
Clinical Data, Inc. provides a full range of products and services to the growing domestic Physician Office Laboratory market and to smaller laboratories internationally & also provides a complete range of products and services for the Physician Office Laboratory and hospital laboratory market.
year
2010
rev ($mm)
$13.09
EBITDA ($mm)
($78.85)
EBIT ($mm)
($81.80)
Net Income ($mm)
Employees
160
  • drill down
  • watch
Ticker: BEAT
 
 
 
 
 
 
 
 
BioTelemetry
BioTelemetry
BioTelemetry, Inc. is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The company currently provides cardiac monitoring services, original equipment manufacturing and more.
year
2019
rev ($mm)
$386.46
EBITDA ($mm)
$110.26
EBIT ($mm)
$69.90
Net Income ($mm)
$48.52
Employees
1500
  • drill down
  • watch
Ticker: ILMN
 
 
 
 
 
 
 
 
Illumina, Inc.
Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets.
year
2020
rev ($mm)
$3,556.00
EBITDA ($mm)
$1,198.00
EBIT ($mm)
$1,013.00
Net Income ($mm)
$942.00
Employees
7700
  • drill down
  • watch